Pentoxifylline as adjuvant therapy in the treatment of major depression

Pentoxifylline as adjuvant therapy in the treatment of major depression: a randomised and double blind study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N116

Enrollment

Registered

2019-03-14

Start date

2019-04-13

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder. Major depressive disorder, single episode, moderate

Interventions

Intervention 1: Intervention group: tablet sertralin 100 mg/day plus Capsule pentoxyfylline 400 mg TDS as intervention group for 6 weeks. Intervention 2: Control group: tablet sertralin 100 mg/day plu

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Presence of Major Depressive Disorder based on DSM-5 criteria Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 19

Exclusion criteria

Exclusion criteria: Presence of psychosis Any other mental disorder Hypothyroidism Cardiovascular disease Pregnancy or nursing women Renal failure Allergy to Theophylline, Aminophylline, and pentoxyfylline Hepatic failure Peptic ulcer Receiving antiplatelets agents or anticoagulants Receiving NSAIDs

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: Baseline and weeks 2,4 and 6. Method of measurement: By Hamiltion Depression Rating Scale 17-Item.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026